Tipentosin is prazosin derivative. It is an angiotensin-converting enzyme inhibitor. Tipentosin was developed as an antihypertensive agent.

Trimoxamine hydrochloride is an antihypertensive agent.

Diprafenone closely resembles propafenone in both structure and function. It is beta adrenoceptor antagonists and sodium channel antagonists. Diprafenone is highly protein bound in plasma. It has demonstrated efficacy against supraventricular and ventricular arrhythmias in clinical trials. Diprafenone produced first-degree atrioventricular block in 6/20 patients tested with coronary artery disease and sustained ventricular tachycardia. Intravenous application of diprafenone significantly increased atrioventricular nodal conduction time as well as the effective refractory periods of the right ventricle and the accessory pathway in both the antegrade and retrograde directions in 15 patients with the Wolff-Parkinson-White syndrome and symptomatic supraventricular tachycardia.

Butoprozine increased the action potential duration like amiodarone, depressed the plateau phase like verapamil and decreased the amplitude and the maximum rate of depolarization. Butoprozine injected intravenously depressed sino-atrial node function, lengthened A-V nodal conduction time and the A-V nodal refractory period, and prolonged the atrial refractory period. Thus butoprozine acted preferentially on parts of the myocardial tissue where the slow inward current seems to be particularly involved. In this respect, butoprozine was more active than amiodarone, but in contrast to this drug, butoprozine did neither prolong the ventricular monophasic action potential duration nor the ventricular refractory period.

ARMGO and Servier are developing an anti-arrhythmia drug aladorian (ARM036) for the treatment of heart failure, arrhythmia and ventricular tachycardia. Aladorian was the first in-house discovered, novel, small molecule NCE (Rycal®) from ARMGO’s library that was advanced into clinical studies. ARM036 completed multiple Phase IIa clinical studies in chronic heart failure patients, demonstrating positive activity and safety in patients, and validating ARMGO’s approach for drug discovery and candidate selection on the RyR target.

Quinuclium Bromide Anhydrous is quinuclidinium derivative with potential analgesic activity. In preclinical studies, Quinuclium possessed significant chronic antihypertensive activity in mecamylamine- and renal-hypertensive dogs. Quinuclium was approximately 4 times more potent than guanethidine in the former model and 3 times as potent in the latter. Quinuclium reduced orthostatic blood pressure responses in unanesthetized rabbits but was approximately 10 times less potent than guanethidine. Quinuclium did not affect cardiac output, heart rate or stroke volume in anesthetized open-chest dogs and moderately increased mean blood pressure and total peripheral resistance. It produced diuresis and saluresis in anesthetized dogs but did not influence water or electrolyte urinary excretion in conscious rats. Quinuclium was more effective than guanethidine in blocking adrenergic neurons and depleting heart norepinephrine levels in experimental animals.

Recainam is an investigational Class I anti-arrhythmic agent that has been studied for its potential in treatment of heart rhythm disorders. No severe adverse events of intravenous recainam adminstration were reported in a study in patients with frequent ventricular premature complexes (extra heart beats) and nonsustained ventricular tachycardia (abnormally fast heartbeat).

Meobentine is an antiarrhythmic agent. Meobentine significantly increases the electrical ventricular fibrillation threshold in animal models. Meobentine may prevent induction of ventricular tachycardia or fibrillation, or reduce frequency of complex ventricular ectopy in selected patients refractory to other antiarrhythmic agents, but the response rate is relatively low.

Recainam is an investigational Class I anti-arrhythmic agent that has been studied for its potential in treatment of heart rhythm disorders. No severe adverse events of intravenous recainam adminstration were reported in a study in patients with frequent ventricular premature complexes (extra heart beats) and nonsustained ventricular tachycardia (abnormally fast heartbeat).